Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Rheum Dis. 2017 Apr;24(2):108-113. English. Case Report. https://doi.org/10.4078/jrd.2017.24.2.108
Park JH , Song JS , Choi ST .
Division of Rheumatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. beconst@hanmail.net
Abstract

The main treatment for Antiphospholipid syndrome (APS) is long-term anticoagulation with an oral vitamin K antagonist, although these are associated with numerous problems. Rivaroxaban is a direct anti-factor Xa inhibitor, with a predictable anticoagulant effect at fixed doses. There are limited reports of rivaroxaban use in APS. We present four cases of patients with APS who received rivaroxaban treatment for six months without thrombosis recurrence or bleeding. Three of the patients received rivaroxaban as initial therapy. In the systematic review, only five patients were treated with rivaroxaban as a thromboprophylaxis. Of the 71 cases of rivaroxaban use including our study, there were seven cases (9.9%) of thrombosis recurrence and two reports of bleeding. The efficacy of rivaroxaban in APS patients was at least equal to warfarin therapy. This report and systematic review suggest that rivaroxaban can be considered cautiously as a thromboprophylactic or alternative therapy for warfarin in patients with APS.

Copyright © 2019. Korean Association of Medical Journal Editors.